Artemisinin-based combination therapy for ... - The Cochrane Library

(Continued)
Proportion with anaemia (Hb < 12g/dl) on
day 14: AS+AQ 40/51 (80.4%) vs AQ+SP
21/27 (77.7%)
In random 25% or study population
Karema 2004 RWA Mean (SD) PCV at day 14: AS+AQ 34.0%
(3.7) vs AQ+SP 34.5 (3.7)
Kayentao 2006 MLI Mean (SD) haemoglobin day 14: AS+AQ
10.17 (1.5) g/dl vs AQ+SP 10.43 (1.49)
g/dl
Mean (SD) haemoglobin day 28: AS+AQ
10.78 (1.49) g/dl vs AQ+SP 11.05 (1.52)
g/dl
Menard 2006 MDG Median (IQR) of individual increases in
Hb from baseline to day 28 (95% CI):
AS+AQ 1.1 g/dl (-2.6 to 5.2) vs AQ+SP
0.5 g/dl (-4.4 to 5.8)
Mutabingwa 2004 TZA Mean (SD) change in haemoglobin from
baseline to Day 14: AS+AQ 0.58 (1.4) g/dl
vs AQ+SP 0.54 (1.4) g/dl
Staedke 2003 UGA Median (SD not reported) change in
haemoglobin from baseline to day 28:
AS+AQ 1.9 g/dl vs AQ+SP 1.3 g/dl
Yeka 2004 UGA Mean increase in haemoglobin by Day 28:
Jinja site: AS+AQ 0.95 (1.91) g/dl vs
AQ+SP 1.15 (1.93) g/dl
Arua site: AS+AQ 1.44 (1.67) g/dl vs
AQ+SP 1.44 (1.60) g/dl
Tororo site: AS+AQ 1.14 (1.48) g/dl vs
AQ+SP 1.58 (1.55) g/dl
Apac site: AS+AQ 1.76 (1.55) g/dl vs
AQ+SP 1.77 (1.79) g/dl
Footnotes
DHA-P = dihydroartemisinin-piperaquine
AS = artesunate
MQ = mefloquine
AL6 = artemether-lumefantrine
AQ = amodiaquine
SP = sulfadoxine-pyrimethamine
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Not significant
P not given
Not significant (P value not given)
Not significant (P value not given)
Not significant
P not given
Not reported
P = 0.004
P > 0.05
P > 0.05
P < 0.05
P > 0.05
239